• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Conferences

Conferences

Mutein IL-2 attenuates antibody-mediated rejection in murine kidney transplantation

August 5, 2025 | World Transplant Congress
Yoshikazu Ganchiku, et al.

Mutein IL-2 attenuates antibody-mediated rejection in murine kidney transplantation

Yoshikazu Ganchiku, Rodrigo Benedetti Gassen, Orhan Efe, Zach Shriver, Greg J. Babcock, Thiago de Jesus Borges, Leonardo V. Riella

Five Strategies to Use IL-2 Muteins to Expand Foxp3+ Treg Cells and Promote Long-term Cardiac and Renal Allograft Survival in Naïve and Sensitized Recipients

August 5, 2025 | World Transplant Congress
Liqing Wang, et al.

Five Strategies to Use IL-2 Muteins to Expand Foxp3+ Treg Cells and Promote Long-term Cardiac and Renal Allograft Survival in Naïve and Sensitized Recipients

Liqing Wang, Luke Robinson, Greg Babcock, Wayne W. Hancock

An IL-2 Mutein (VIS171) Induces Regulatory T Cells and Prolongs Survival in a Rhesus Kidney Transplant Model

August 5, 2025 | World Transplant Congress
Davide Schiliró, et al.

An IL-2 Mutein (VIS171) Induces Regulatory T Cells and Prolongs Survival in a Rhesus Kidney Transplant Model

Davide Schiliró, Matthew Tunbridge, Alessandro Martinino, Joe M. Ladowski, Nagham Bazzi, Meghan Hu, Allie Schwalb, Kyo Won Lee, Min Jung Kim, Zishen Li, Janghoon Yoon, Angela Park, Rafaela Belloni, Zheng Chen, John J. O’Neil, Asher D. Schachter, David Oldach, Gregory J. Babcock, Kyha Williams, Jean Kwun, Stuart Knechtle

Selective Enrichment and Functional Preservation of Treg Cells During IL-2 Mutein-Mediated Expansion and Contraction

August 2, 2025 | World Transplant Congress
Davide Schiliró, et al.

Selective Enrichment and Functional Preservation of Treg Cells During IL-2 Mutein-Mediated Expansion and Contraction

Davide Schiliró, Ming Sun, Joshua Lopez, Tammy Tollison, Ethan Smith, Matt Tunbridge, Alessandro Martinino, John J. O’Neil, Asher D. Schachter, David Oldach, Gregory J. Babcock, Stuart Knechtle, Xinxia Peng, H. Kay Chung, Jean Kwun

C5aR1 inhibition ameliorates DGF in a DCD porcine kidney auto-transplantation model

August 2, 2025 | World Transplant Congress
Nader Abraham, et al.

C5aR1 inhibition ameliorates DGF in a DCD porcine kidney auto-transplantation model

Nader Abraham, John J. O’Neil, Mohamed Diab, Ahmed Hassan, Ewout Muylle, Nihal Aykun, Bangchen Wang, David Oldach, Mohit Mathur, Tressa Hood, Benjamin Hughe, Andrew S. Barbas

Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study

June 6, 2025 | 62nd ERA Congress
Vlado Perkovic, et al.

Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study

Vlado Perkovic, Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll, Chee Kay Cheung, Vladimir Tesař, Hernán Trimarchi, Muh Geot Wong, Hong Zhang, Dana V. Rizk

>SEE PRESENTATION

Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity

June 5, 2025 | 62nd ERA Congress
Kirk Rowley, et al.

Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity

Kirk Rowley, Vinay Singh, Anna Roberts, Katie Heang, Prashanna Venkatasubramanian, Jacob Konaklonda, Daved Fared, Michelle Lu, Brett Hurst, Wayne W. Hancock, Gregory J. Babcock, Luke Robinson

>SEE POSTER

Preclinical Development of VIS171 – A Novel Modified IL-2 Safely and Selectively Upregulates Regulatory T Cells to Treat Autoimmune Diseases

September 6, 2024 | Promise of Interleukin-2 Therapy Conference
John J. O’Neil, et al.

Preclinical Development of VIS171 – A Novel Modified IL-2 Safely and Selectively Upregulates Regulatory T Cells to Treat Autoimmune Diseases

John J. O’Neil, Greg J. Babcock, Zach Shiver, David Oldach, Susan Sloan

Modified-IL-2 (VIS171) to Preferentially Induce Regulatory T Cells in Nonhuman Primates

September 6, 2024 | Promise of Interleukin-2 Therapy Conference
John J. O’Neil, et al.

Modified-IL-2 (VIS171) to Preferentially Induce Regulatory T Cells in Nonhuman Primates

John J. O’Neil, Davide Schiliró, Joe M. Ladowski, Janghoon Yoon, Angela Park, Rafaela Belloni, Asher D. Schachter, David Oldach, Gregory J. Babcock, Jean Kwun, Stuart Knechtle

Tissue-resident ST2+ regulatory T cells promote cardiac transplant tolerance induced by a mutein IL-2

June 2, 2024 | American Transplant Congress
Yoshikazu Ganchiku, et al.

Tissue-resident ST2+ regulatory T cells promote cardiac transplant tolerance induced by a mutein IL-2

Yoshikazu Ganchiku, Rodrigo Gassen, Orhan Efe, Zach Shriver, Gregory J. Babcock, Thiago J. Borges, Leonardo V. Riella

  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »

© 2025 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design

We use cookies on our website to see how you interact with it. By accepting, you agree to our use of such cookies. Privacy PolicyOk